Canada's PAH patients near access to Merck's groundbreaking WINREVAIR® treatment

A new treatment for pulmonary arterial hypertension (PAH) has moved closer to public funding in Canada. Merck, known as MSD outside North America, has finalised negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The drug is designed for adults with WHO Group 1 PAH who are already receiving standard therapy.

PAH is a serious condition where narrowed arteries in the lungs restrict blood flow and lower oxygen levels. Without treatment, it can lead to heart strain, mobility issues, and a shorter lifespan.

WINREVAIR® is approved for patients with Functional Class (FC) II or III PAH. The condition often causes symptoms like breathlessness, fatigue, swollen legs, chest pain, and dizziness. These signs can develop gradually and may be confused with other heart or lung problems.

The pCPA agreement marks a key step toward public reimbursement in Canada. Next, provincial, territorial, and federal drug programmes will need to set up fair reimbursement plans based on patient eligibility criteria.

Dr. Jason Weatherald, a pulmonologist at the University of Alberta, stressed the value of having more treatment options. He noted that additional therapies allow clinicians to better tailor care for PAH patients. Jamie Myrah, Executive Director of the Pulmonary Hypertension Association of Canada, also highlighted the need for broad and equal access to innovative treatments like WINREVAIR®.

Merck, a global biopharmaceutical company, focuses on using advanced science to improve and save lives. The firm's latest agreement brings WINREVAIR® one step nearer to patients who could benefit from it.

The completion of pCPA negotiations means WINREVAIR® is now closer to being publicly funded across Canada. Provincial and federal health bodies will determine how eligible patients can access the treatment. The drug offers a new option for those managing PAH alongside existing therapies.